Get the Stockscreener App
18.55
0.71%
+0.13
After Hours:
18.49
-0.06
-0.32%
Organon & Co. stock is currently priced at $18.55, with a 24-hour trading volume of 1.99M.
It has seen a +0.71% increased in the last 24 hours and a +2.37% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $18.45 pivot point. If it approaches the $18.70 resistance level, significant changes may occur.
Previous Close:
$18.42
Open:
$18.43
24h Volume:
1.99M
Market Cap:
$4.74B
Revenue:
$6.26B
Net Income/Loss:
$1.02B
P/E Ratio:
8.1004
EPS:
2.29
Net Cash Flow:
$538.00M
1W Performance:
+4.10%
1M Performance:
+2.37%
6M Performance:
+21.16%
1Y Performance:
-21.73%
1D Range:
$18.33
$18.68
52W Range:
$10.84
$24.79
Organon & Co. Stock (OGN) Company Profile
Name
Organon & Co.
Sector
Industry
Phone
551 430 6000
Address
30 Hudson Street, Jersey City
Organon & Co. Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon & Co. Stock (OGN) Latest News
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
Zacks Investment Research
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
Zacks Investment Research
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know
Zacks Investment Research
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
Zacks Investment Research
Organon (OGN) Advances While Market Declines: Some Information for Investors
Zacks Investment Research
Molina (MOH) Wins Deal to Serve Michigan's Medicaid Members
Zacks Investment Research
Organon & Co. Stock (OGN) Financials Data
Organon & Co. (OGN) Revenue 2024
OGN reported a revenue (TTM) of $6.26 billion for the quarter ending December 31, 2023, a +1.44% rise year-over-year.
Organon & Co. (OGN) Net Income 2024
OGN net income (TTM) was $1.02 billion for the quarter ending December 31, 2023, a +11.56% increase year-over-year.
Organon & Co. (OGN) Cash Flow 2024
OGN recorded a free cash flow (TTM) of $538.00 million for the quarter ending December 31, 2023, a +24.83% increase year-over-year.
Organon & Co. (OGN) Earnings per Share 2024
OGN earnings per share (TTM) was $4.00 for the quarter ending December 31, 2023, a +11.42% growth year-over-year.
Organon & Co. Stock (OGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nisita Vittorio | Head of Global Business Svcs |
Mar 31 '24 |
Option Exercise |
0.00 |
7,469 |
0 |
22,597 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '24 |
Option Exercise |
0.00 |
19,799 |
0 |
90,042 |
| Fiedler Susanne | Chief Commercial Officer |
Mar 31 '24 |
Option Exercise |
0.00 |
12,565 |
0 |
49,747 |
| Morrissey Joseph T. Jr. | Head of Manufacturing |
Mar 31 '24 |
Option Exercise |
0.00 |
11,730 |
0 |
41,130 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Mar 31 '24 |
Option Exercise |
0.00 |
13,619 |
0 |
29,159 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '24 |
Option Exercise |
0.00 |
10,309 |
0 |
30,900 |
| Ali Kevin | Chief Executive Officer |
Mar 31 '24 |
Option Exercise |
0.00 |
60,444 |
0 |
146,896 |
| DiMarco Kathryn | Corporate Controller |
Mar 31 '24 |
Option Exercise |
0.00 |
12,797 |
0 |
23,063 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Feb 22 '24 |
Buy |
18.36 |
2,720 |
49,939 |
15,181 |
| DiMarco Kathryn | Corporate Controller |
Feb 09 '24 |
Option Exercise |
0.00 |
1,871 |
0 |
9,388 |
About Organon & Co.
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
0.49%
0.47%
Cap:
|
Volume (24h):